Latest Commercialization News

Everest Metals Corporation, in partnership with Edith Cowan University, has won a $490,500 grant to accelerate its innovative rubidium extraction technology at the Mt Edon project, positioning Australia to establish its first sovereign rubidium supply.

Pointerra Limited reported a 30% increase in customer receipts to A$2.6 million and positive operating cashflows in Q2 FY26, driven by major contracts including a US$2 million DOE grant with Georgia Power. The company’s digital twin SaaS platform continues to expand across key sectors, positioning it for sustained growth.

Mayfield Childcare Limited’s board has issued a Target’s Statement recommending shareholders reject Embark Early Education’s unsolicited takeover offer, citing undervaluation and significant risks. The offer, which includes a scrip or cash option, is seen as opportunistically timed amid Mayfield’s operational turnaround.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

Nanoveu Limited has raised A$7.5 million through a strategic placement to accelerate the commercial rollout of its cutting-edge EMASS ECS-DoT semiconductor technology, including a rapid 16nm chip tape-out and live drone validation.

Blue Star Helium has achieved its first helium production at the Galactica Project, marking a key milestone as it optimizes plant operations and prepares for commercial ramp-up.

Neurizon Therapeutics has secured trademark protection for its NEURIZON® brand across major pharmaceutical markets, reinforcing its intellectual property strategy as it advances its lead drug candidate NUZ-001.

FBR Limited has secured a binding conditional purchase order worth AUD 990,000 from a leading US heavy equipment dealer for its Mantis welding robot, marking a significant milestone during its prototyping phase.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

Australian Rare Earths has demonstrated a low-risk, scalable process producing a high-purity mixed rare earth oxide with 99.9% recovery, positioning its Koppamurra project as a strategic supplier amid tightening global rare earth markets.

Origin Energy has announced it will keep the Eraring Power Station operational until April 2029, extending its life by nearly two years to bolster NSW’s energy security during the shift to renewables.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.